Enovis Corporation/$ENOV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enovis Corporation
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Ticker
$ENOV
Sector
Primary listing
NYSE
Employees
7,367
Headquarters
Website
ENOV Metrics
BasicAdvanced
$1.9B
-
-$14.68
1.81
-
Price and volume
Market cap
$1.9B
Beta
1.81
52-week high
$49.38
52-week low
$25.47
Average daily volume
1.1M
Financial strength
Current ratio
2.253
Quick ratio
0.876
Long term debt to equity
55.084
Total debt to equity
56.753
Interest coverage (TTM)
0.85%
Profitability
EBITDA (TTM)
353.374
Gross margin (TTM)
60.28%
Net profit margin (TTM)
-37.80%
Operating margin (TTM)
2.96%
Effective tax rate (TTM)
-3.73%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
0.89%
Return on equity (TTM)
-28.25%
Valuation
Price to revenue (TTM)
0.858
Price to book
0.74
Price to tangible book (TTM)
-3.49
Price to free cash flow (TTM)
-475.307
Free cash flow yield (TTM)
-0.21%
Free cash flow per share (TTM)
-0.07
Growth
Revenue change (TTM)
14.40%
Earnings per share change (TTM)
786.30%
3-year revenue growth (CAGR)
12.70%
10-year revenue growth (CAGR)
-6.54%
3-year earnings per share growth (CAGR)
89.62%
10-year earnings per share growth (CAGR)
9.02%
Bulls say / Bears say
Enovis’ second-quarter 2025 net sales rose 7% year-over-year to $564.54 million, surpassing analyst expectations and reflecting steady end markets and strong product momentum. (Reuters)
The company’s Q2 adjusted earnings per share of $0.79 beat consensus by $0.07, showing higher operational efficiency. (Reuters)
Enovis raised its full-year 2025 revenue outlook to $2.245–$2.275 billion and increased adjusted EPS guidance to $3.05–$3.20, signaling management’s confidence in sustained growth. (Reuters)
Enovis cut its annual adjusted profit outlook to $2.95–$3.10 per share from $3.10–$3.25, indicating margin pressure from tariffs and integration costs. (Reuters)
Shares are underperforming due to tariff concerns, according to Evercore ISI, reflecting worry about the company’s $40 million annual tariff exposure. (Reuters)
Enovis shares dropped 4% after reiterating its Q1 revenue forecast with no update to full-year guidance, adding to an 18.6% year-to-date decline. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enovis Corporation stock?
Enovis Corporation (ENOV) has a market cap of $1.9B as of September 17, 2025.
What is the P/E ratio for Enovis Corporation stock?
The price to earnings (P/E) ratio for Enovis Corporation (ENOV) stock is 0 as of September 17, 2025.
Does Enovis Corporation stock pay dividends?
No, Enovis Corporation (ENOV) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Enovis Corporation dividend payment date?
Enovis Corporation (ENOV) stock does not pay dividends to its shareholders.
What is the beta indicator for Enovis Corporation?
Enovis Corporation (ENOV) has a beta rating of 1.81. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.